1311197-90-6

Basic information

• Product Name: 6-Bromo-3-cyclopropyl-1H-indazole
• Synonyms: 6-Bromo-3-cyclopropyl-1H-indazole
• CAS NO: 1311197-90-6
• Molecular Formula: C10H9BrN2
• Molecular Weight: 237.09586
• Mol File: 1311197-90-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 394.2±22.0 °C(Predicted)
• Appearance: /
• Density: 1.702±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.17±0.40(Predicted)
• CAS DataBase Reference: 6-Bromo-3-cyclopropyl-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-3-cyclopropyl-1H-indazole(1311197-90-6)
• EPA Substance Registry System: 6-Bromo-3-cyclopropyl-1H-indazole(1311197-90-6)

Safety Data

• Hazardous Substances Data: 1311197-90-6(Hazardous Substances Data)

Usage

General Description

6-Bromo-3-cyclopropyl-1H-indazole is a chemical compound with the molecular formula C10H9BrN2. It is a substituted indazole derivative, meaning it has a core structure of indazole with a bromine atom and a cyclopropyl group attached. 6-Bromo-3-cyclopropyl-1H-indazole is of interest in the field of medicinal chemistry due to its potential pharmaceutical properties, such as anticonvulsant and antinociceptive effects. It may also have applications in research related to the central nervous system and neurological disorders. The exact mechanisms of action and potential therapeutic uses of 6-Bromo-3-cyclopropyl-1H-indazole are still being investigated.

Upstream product

• 898790-15-3 (4-bromo-2-fluorophenyl)(cyclopropyl)methanone 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 

Relevant articles and documents

NOVEL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS

The invention relates to novel indole and indazole compounds characterized in that the compound has general formula (I), in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicament

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.